TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01477983

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ATP guide additional ablation.
Description: Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug (AAD)
Description: Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ATP guide additional ablation.
Description: Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Following successful PV isolation, intravenous ATP is not administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug (AAD)
Description: Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Following successful PV isolation, intravenous ATP is not administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
Study: NCT01682525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frozen ovarian tissue
Description: Use of ovarian tissue cryopreserved and stored at Boston IVF
Study: NCT03129646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: Miltefosine 10mg and 50mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: Miltefosine 10mg and 50mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin
Description: Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin
Description: Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paromomycin
Description: Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium stibogluconate
Description: Sodium stibogluconate 33% 30 ml inj.
Study: NCT04156529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESU position
Description: Semi-elevated supine (ESU) position was given during tube feeding

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESU position
Description: Semi-elevated supine (ESU) position was given during tube feeding

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESRL position
Description: Semi-elevated right lateral (ESRL) position was given during tube feeding

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESRL position
Description: Semi-elevated right lateral (ESRL) position was given during tube feeding
Study: NCT01642368

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Optimum Omega-3 Fatty Acid Feeding Study
Description: Assess whether swapping specific food ingredients in the diet can significantly improve polyunsaturated fatty acid blood profiles and improve a person's response to cognitive measures and physical fitness.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Optimum Omega-3 Fatty Acid Feeding Study
Description: Assess whether swapping specific food ingredients in the diet can significantly improve polyunsaturated fatty acid blood profiles and improve a person's response to cognitive measures and physical fitness.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: The Optimum Omega-3 Fatty Acid Feeding Study
Description: Assess whether swapping specific food ingredients in the diet can significantly improve polyunsaturated fatty acid blood profiles and improve a person's response to cognitive measures and physical fitness.
Study: NCT01971177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser cataract surgery
Description: The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.~The correct positioning of the cuts inside the lens can be verified by means of an optical coherence tomograph (OCT) before starting the laser assisted fragmentation process.~Various surgical patterns will be used within this study. For each pattern different geometry/laser parameters can be adjusted individually according to each patient's cataract status.~All the patients who are enrolled in the laser groups (all cataract grades) will be treated with femtosecond laser assisted capsulotomy before the femtosecond laser assisted lens fragmentation by VICTUS femtosecond laser platform.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual cataract surgery
Description: Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation
Study: NCT03116230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutaneous Stimulation
Description: A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutaneous Stimulation
Description: A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee Sleeve
Description: Commercially-available knee sleeve.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee Sleeve
Description: Commercially-available knee sleeve.
Study: NCT00858546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial stimulation
Description: Repetitive transcranial stimulation
Study: NCT02818673

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: labelled human serumalbumin (125-I, Séralb®CisBio)
Description: Intra-veinous injection of 0,015 MBq/Kg ; 0,5 to 2 mL injected over less than a minute

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: labelled albumin (99m-Tc, Vasculocis®, Cisbio)
Description: intra-peritoneal injection of 200 MBq of labelled albumin (99m-Tc, Vasculocis®, Cisbio) ; 5 ml injected over less than a minute
Study: NCT01440920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCV-501
Description: subcutaneously administered once a week, 4 times at the dose of 0.3 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCV-501
Description: subcutaneously administered once a week, 4 times at the dose of 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCV-501
Description: subcutaneously administered once a week, 4 times at the dose of 3 mg
Study: NCT05084456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
Study: NCT02401230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gel lubricant
Description: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gel lubricant
Description: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.
Study: NCT03033615

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PixelShine
Description: Machine learning algorithm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PixelShine
Description: Machine learning algorithm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional processing
Description: Iterative reconstruction software

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional processing
Description: Iterative reconstruction software
Study: NCT01194310

Intervention type: PROCEDURE
Intervention: phaco
Description: Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) alone
Study: NCT03396965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mini-c-arm
Description: Fluoroscopy used to aid reduction of distal radius fracture
Study: NCT01834729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: oral alfuzosin immediate release (IR) 2.5 mg (Part A) or oral alfuzosin extended release (ER) 10 mg (Part B)
Study: NCT01194310

Intervention type: PROCEDURE
Intervention: phaco
Description: Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) alone

Intervention type: PROCEDURE
Intervention: phaco
Description: Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) alone

Intervention type: PROCEDURE
Intervention: phaco-ELT
Description: Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus excimer laser trabeculotomy (ELT)

Intervention type: PROCEDURE
Intervention: phaco-Trabectome
Description: Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus Trabectome
Study: NCT01418898

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Intervention
Description: Nutrient fortified oat beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Nutrient fortified oat beverage
Study: NCT00870701

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 50 grays in 25 fractions of 2 Gys or 50.4 grays in 28 fractions of 1.8 grays

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: absence of radiotherapy
Description: absence of radiotherapy
Study: NCT04087590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol-glycopyrronium co suspension (PT003)
Description: Formoterol-glycopyrronium co suspension (PT003) in a Metered Dose Inhaler, 2 puffs twice daily
Study: NCT01053832

Intervention type: DEVICE
Group type: OTHER
Intervention: VpS algorithm in EVIA and ENTOVIS pacemakers
Description: For one group of patients, the VpS algorithm will be activated and for the other group, the VpS algorithm will be deactivated until the cross-over, where these conditions will be switched.

Intervention type: DEVICE
Group type: OTHER
Intervention: VpS algorithm in EVIA and ENTOVIS pacemakers
Description: For one group of patients, the VpS algorithm will be activated and for the other group, the VpS algorithm will be deactivated until the cross-over, where these conditions will be switched.
Study: NCT02497066

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neuropathic pain cream
Description: Subjects will apply the cream to the painful area.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nociceptive pain cream
Description: Subjects will apply the cream to the painful area.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mixed pain cream
Description: Subjects will apply the cream to the painful area.
Study: NCT03179384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: ceftriaxone (1g intravenous or 1g/35mL intramuscular) will be given to patients during 7 days
Study: NCT02474641

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Radiation
Description: Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or~Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or~Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation with SIB
Description: Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed
Study: NCT04240873

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Catholic MASTER cell
Description: Injection of CATHOLIC MASTER cells 1 x 10\^8 cells/DMEM 5cc into knee of patents with osteoarthritis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Injection of saline 5cc into knee of patents with osteoarthritis
Study: NCT01866254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Injection of 100 mcg hydromorphone into the intrathecal space
Study: NCT01834729

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule identical to the study drug
Study: NCT01441570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Subject will take nebivolol daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Description: Subject will take metoprolol succinate daily for 12 weeks.
Study: NCT01127165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonisamide low dose group
Description: Initial dose was 2mg/kg/day, increased after 1\~2 weeks to 3\~4mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonisamide high dose group
Description: Initial dose was 2mg/kg/day, increased after 2\~4 weeks to 6\~8mg/kg/day.
Study: NCT01554930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge)
Description: Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiyanping injection plus western therapy
Description: Xiyanping injection:5-10mg/kg/d (0.2-0.4ml/kg/d),qd ivgtt; Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
Study: NCT02695511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: 25% caloric restriction below baseline energy requirement
Study: NCT04293679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Investigational Product
Study: NCT01137383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaferon (pegylated interferon alpha 2a) + ribavirin
Description: pegylated interferon 180 micrograms subcutaneously weekly - ribavirin (oral, in two divided daily doses) 800 mg for genotype 2 and 3, 1000 or 1200mg (weight less than or greater than 75kg) for genotypes 1 and 4 - Duration: 24 weeks for genotype 2 and 3, 48 weeks for genotypes 1 and 4
Study: NCT00931398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate HCl (Concerta)
Description: Concerta 18 mg, 36 mg, 54 mg, and 72 mg q.am.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo for all Concerta doses.
Study: NCT04192409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Application
Description: Patients will use a smartphone application contain the following functions: providing health education information about DM and CAD, reminding patients to take medicine on time by alarm, recording patients' recent fast plasma glucose value.
Study: NCT05175807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness (e.g., body scan, gentle yoga, sitting, grounding, and walking meditation), relaxation techniques, and cognitive rehabilitation exercises.
Study: NCT03032276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safe motherhood and newborn health promotion package
Description: The intervention package consists of three components: facility, community and linkages between the community and health facilities. Facility based interventions will serve both the comparison and intervention arms. However, other two interventions will serve the intervention arm only. Specific interventions and approaches for the three components will be implemented within the MOH\&FW service delivery system to improve MNH practices in families and communities and to increase the use of MNH services from appropriate facilities/providers. The intervention package has been developed based on the experiences from SMPP in Narsingdi district and on the basis of consultations with the International Advisory Body (IAB) that included GoB, JICA, ICDDR,B, other experts and stakeholders.
Study: NCT03144466

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: antiPD1 monoclonal antibody

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: antiPD1 monoclonal antibody

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: antiPD1 monoclonal antibody
Study: NCT00985400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Resistance exercising using resistance bands 2 days per week, and brief moderate-intensity walks multiple times a day for a total of 30 minutes increasing steps weekly by 10% to reach a minimum of 10,000 steps a day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention
Description: Patients will receive encouragement and social support from a telephone counselor once a week for the first 4 weeks and then once a month for the remaining 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention
Description: Patients will receive encouragement and social support from a telephone counselor once a week for the first 4 weeks and then once a month for the remaining 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling intervention
Description: Patients will receive advice from their doctor (in person), physician assistant, or other midlevel provider about exercising. They will also be given this advice in a letter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling intervention
Description: Patients will receive advice from their doctor (in person), physician assistant, or other midlevel provider about exercising. They will also be given this advice in a letter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Program
Description: Relaxation techniques (breathing and meditation) provided at least 15 minutes per day for 5-7 days per week.
Study: NCT01882946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVax-Direct
Description: Autologous, activated dendritic cells for intratumoral injection
Study: NCT04279015

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio tape procedure
Description: Conventional rehabilitation treatment: Hotpack, ultrasound, conventional TENS and exercise for neck pain.~Kinesio taping procedure: Inhibition technique with 15-25% tension to the upper trapezius muscle with I tape to reduce pain and muscle spasm, to support the weak muscles, Facilitation technique with Y-band with 15-35% tension to the cervical paravertebral muscles, and X-band with 15-35% tension to the rhomboideus major muscle technique and the correction technique was applied to the region where the individual defined the most pain and tenderness in palpation by using the star application.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio tape procedure
Description: Conventional rehabilitation treatment: Hotpack, ultrasound, conventional TENS and exercise for neck pain.~Kinesio taping procedure: Inhibition technique with 15-25% tension to the upper trapezius muscle with I tape to reduce pain and muscle spasm, to support the weak muscles, Facilitation technique with Y-band with 15-35% tension to the cervical paravertebral muscles, and X-band with 15-35% tension to the rhomboideus major muscle technique and the correction technique was applied to the region where the individual defined the most pain and tenderness in palpation by using the star application.
Study: NCT05599997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pecavaptan (BAY1753011)
Description: 30 mg, immediate release tablet, single dose, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pecavaptan (BAY1753011)
Description: 30 mg, immediate release tablet, single dose, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pecavaptan (BAY1753011)
Description: 30 mg, immediate release tablet, single dose, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pecavaptan (BAY1753011)
Description: 15 mg, immediate release tablet, single dose, oral